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Coronary computed tomographic angiography (CCTA) employing CT scanners of 64-
detector rows or greater represents a noninvasive method that enables accurate detec-
tion and exclusion of anatomically obstructive coronary artery disease (CAD), providing
excellent diagnostic information when compared to invasive angiography. There are
numerous potential advantages of CCTA beyond simply luminal stenosis assessment
including quantification of atherosclerotic plaque volume as well as assessment of plaque
composition, extent, location and distribution. In recent years, an array of studies has
evaluated the prognostic utility of CCTA findings of CAD for the prediction of major adverse
cardiac events, all-cause death and plaque instability. This prognostic information en-
hances risk stratification and, if properly acted upon, may improve medical therapy and/or
behavioral changes that may enhance event-free survival. The goal of the present article is
to summarize the current status of the prognostic utility of CCTA findings of CAD.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction In particular, CCTA demonstrates a very high negativeCurrent professional societal guidelines endorse the use of
noninvasive imaging tests for the diagnostic evaluation of
symptomatic patients with at least intermediate pre-test like-
lihood of anatomically obstructive coronary artery disease
(CAD). These tests have historically comprised physiologic
stress testing by electrocardiography, echocardiography, car-
diac magnetic resonance and myocardial perfusion imaging
(MPI). More recently, coronary computed tomographic angiog-
raphy (CCTA) has emerged as a noninvasive anatomic alter-
native that has gained increasingutilizationand importance for
the diagnosis of CAD, with generally high diagnostic perfor-
mance compared to invasive coronary angiography (ICA).cine, Imaging, and Biome
er Building, Room 1253, L
. Otaki), james.min@csh
2013, Cardiological Sociepredictive value for the exclusion of anatomically obstructive
CAD, whichmay prove useful for preventing unnecessary ICA.
Recent data from the National Cardiovascular Death Registry
revealed that, amongst 398,978 patients who underwent
elective ICA at 663 hospitals between January 2004 through
April 2008, 39.2% of patients had no evidence of significant
CAD, defined as <20% stenosis in any vessels.1 Notably,
noninvasive examinations, including stress testing, were
performed in 83.9% of the patients in this study population
prior to ICA. These findings suggest the need for improved
noninvasive measures to curb unnecessary ICA, and pro-
ponents of CCTA have posited this anatomic test as a means
to achieve this goal.dical Sciences, Cedars-Sinai Heart Institute, Cedars-Sinai Medical
os Angeles, CA 90048, USA. Tel.: þ1 310 423 2707; fax: þ1 310 423
s.org (J.K. Min).
ty of India. All rights reserved.
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have been introduced to improve multi-detector computed
tomography (CT) technology, including the introduction of 64-
detector row CT scanners in 2005, which enabled the reliable
acquisition of generally motion-free images of the coronary
arteries and allowing for assessment of coronary stenosis and
atherosclerotic plaque. Since the introduction of 64-detector
row scanners, an array of newer generation scanners have
been introduced to improve upon the spatial and temporal
resolution as well as the volume coverage. These have
included high-definition scanners capable of 230 micron in-
plane resolution; dual source and fast pitch helical scanners
that achieve temporal resolution of 83 ms; and wide area de-
tector CT which allow for 16 cm coverage within a single
gantry revolution, therein allowing whole heart coverage
during a single heart beat.
In a recent meta-analysis of 27 studies using 16 to 64-slice
scanner, CCTA was reported to have a diagnostic sensitivity,
specificity, negative predictive value (NPV), and positive pre-
dictive values (PPV) of 99%, 89%, 93% and 100%, respectively.2
These meta-analytic findings mirror those of prospective
multicenter trials. One such trial, the ACCURACY (Assessment
by Coronary Computed Tomographic Angiography of In-
dividuals Undergoing Invasive Coronary Angiography)
studydrepresented the first prospective multicenter study
evaluating 230 stable patients without known coronary artery
disease undergoing CCTA before ICA3ddemonstrated a diag-
nostic sensitivity, specificity, PPV, and NPV of 95%, 83%, 64%,
and 99%, respectively, compared to a quantitative coronary
angiographic reference standard. Subsequent to the ACCU-
RACY study, two additional prospective multicenter studies
also demonstrated high sensitivity, negative predictive value,
and high diagnostic accuracy of 64-slice CCTA compared to
invasive coronary angiogramdin particular for patients
without known CADdwith study results similar to the AC-
CURACY trial.4,5
One additional potential benefit of CCTA is its ability to
characterize andquantify coronary atherosclerotic plaque and
arterial wall features in addition to providing accurate evalu-
ation of degree of coronary stenosis. Numerous prior studies
have compared the ability of CCTA to characterize and quan-
tify coronary plaque to a gold standard, typically employing
gray scale intravascular ultrasound (IVUS).6 In a recent meta-
analysis of 33 studies that comprised 946 patients, CCTA was
noted to demonstrate excellent correlation to IVUS for
numerous additional atherosclerotic measures beyond steno-
sis severity, including cross sectional area, plaque area, area
stenosis, plaque volume and arterial remodeling.7Table 1 e Prognostic CCTA studies for mortality.
No Author Year Study type No of patients T
1 Min8 2007 Retrospective 1127
2 Ostrom9 2008 Retrospective 2538
3 Min11 2010 Retrospective 5330
4 Lin10 2011 Prospective 2583
CCTA ¼ coronary CT angiography; mo ¼months; CAD ¼ coronary arteryIn addition to its high diagnostic performance against
invasive angiography and IVUS, CCTA findings of CAD have
been evaluated for its ability to predict future adverse CAD
events. We herein describe the most current findings from
CCTA studies evaluating its prognostic utility for future
adverse events.2. Prognostic value of CCTA for all-cause
death from initial studies
The first large single center prognostic study evaluated the
association of all-cause mortality with CCTA defined extent
and severity of CAD in 1127 patients with suspected disease.8
In this study, the per-patient, per-vessel and per-segment
stenosis severity by 16-detector raw CCTA was scored as
minimal (<30%), mild (30%e49%), moderate (50%e69%), or
severe (70%). Atherosclerotic plaque was assessed by 3
distinct methods: 1) presence or absence of moderate or se-
vere plaque; 2) coronary artery plaque burden as categorized
by a modified Duke CAD index; and 3) simple clinical scores
grading plaque extent and distribution. During a 15 month
follow-up period, CCTA predictors of death included proximal
left anterior descending artery (LAD) stenosis and number of
vessels with 50% and 70% stenosis (all p < 0.0001).
Furthermore, survival worsenedwith higher-risk Duke scores,
ranging from 96% survival for 1 stenosis 70% or 2 stenoses
50% ( p < 0.013) to 85% survival for 50% left main (LM) artery
stenosis ( p < 0.0001). In addition, clinical scores measuring
plaque burden and distribution predicted 5e6% higher abso-
lute death rate (6.6% vs. 1.6% and 8.4% vs. 2.5%; p < 0.05 for
both). Importantly, a negative CCTA was noted to provide an
extremely low risk for death. Subsequent to this initial inves-
tigation, multiple studies to date examined the prognostic
value of 64-detector row CCTA have done so, but were gener-
ally limited to single centers and/or relatively small sample
sizes9,10 (Table 1). One large-scale 2-center study examined
5330 consecutive patients without known CAD undergoing
CCTA.11 At 2.3 0.6 year follow-up for an endpoint of all-cause
mortality, obstructive CAD  70% correlated with higher inci-
dent death [hazards ratio (HR) 2.44, 95%confidence interval (CI)
1.61e3.72, p < 0.001]. Compared to those without obstructive
CAD, individuals with increasing numbers of vessels with
obstructive CAD experienced increased risk of death: 1-vessel
(HR 2.23, 95%CI 1.34e3.72), 2-vessel (HR 3.29, 95%CI 1.62e6.71),
or 3-vessel (HR 7.35, 95% CI 3.79e14.29) (p < 0.001 for all).
Further, bymeasures of left ventricular ejection fraction (LVEF)
made possible by retrospective electrocardiographic gating,ime of follow-up Population Slice of CCTA
15  4 mo Patients 45 years old,
chest symptoms
16
78  12 mo Symptomatic 64
2  1 years Without known CAD 64
3  1 years non-obstructive CAD 64
disease.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 3 0 0e3 1 0302individuals with LVEF >50% e when compared to those with
LVEF  50% e exhibited higher rates of death (HR 1.56, 95% CI
1.04e2.36, p ¼ 0.03). When combined, annualized mortality
rates in those with non-obstructive CAD and LVEF> 50%were
low (0.51%) and increasedaccordingly fornon-obstructiveCAD
and LVEF  50% (0.74%), obstructive CAD and LVEF > 50%
(1.76%), and obstructive CAD and LVEF 50% (3.97%) (log-rank
test p < 0.001).3. Prognostic value of CCTA for major
adverse cardiovascular event (MACE)
Although prior numerous studies have assessed the prognostic
value of CCTA findings formortality, relatively few studies have
examined risk stratification of CAD findings by CCTA for pre-
diction of major adverse cardiovascular events (MACE). These
studies, similar to the initial mortality investigations, were
limited by small samples at single centers with short to inter-
mediate follow-up periods12e21 (Table 2). Of these, one of the
larger scale studies with relatively longer follow-up was per-
formed by Hadamitzky et al.22 At 18 months of follow-up, they
prospectively identified among 1256 patients with suspected
CAD the occurrence of MACE, inclusive of cardiac death,
myocardial infarction (MI), or unstable angina requiring hospi-
talization; these were defined as “severe” CAD events. Further,
they investigated the prognostic utility of CCTAwhen including
targetvessel revascularization>90daysafterCCTA. Inthisstudy
in 802 patients without obstructive CAD, there were 4 cardiac
events, of which 1 was severe, whereas in 348 patients with
obstructive CAD, there were 17 cardiac events, of which 5 were
severe. The difference between the 2 groups was highly signifi-
cantboth for severeevents [OR:17.3, 95%CI: 3.6 to 82.5 and forall
cardiac events (OR: 16.1, 95% CI: 7.2 to 36.0; both p < 0.001). A
recent meta-analysis of 10 studies with 64-slice CCTA showed
that the cumulative MACE rate over 21 months were 0.5% in
patientswithnormalCTA, 3.5% innon-obstructiveCADand16%
inobstructiveCAD.23Compared tonormalCTA,non-obstructive
CADwasassociatedwithsignificant increasedriskofMACEwith
OR ¼ 6.68 (3.01e14.82 95% CI), p ¼ 0.0001. Obstructive CAD was
associated with further significant increased risk of MACE with
OR ¼ 41.19 (22.56e75.18, 95% CI), p¼ 0.0001.Table 2 e Prognostic CCTA studies for major adverse cardiova
No. Study Year No. of
patients
Follow-up
1 Pundziute12 2007 100 16 mo Known or
2 Gaempeli13 2008 220 14  4 mo Known or
3 Aldrovandi14 2009 187 24 mo Suspected
4 Carrigan15 2009 227 2  1 years Suspected
5 Hadamitzky22 2009 1150 18 mo Suspected
6 Rubinshtein16 2009 545 18  6 mo Suspected
7 Gopal17 2009 454 40  9 mo Suspected
8 Abidov18 2009 199 2 years Sequentia
10 Motoyama27 2009 1059 27  10 mo Known or
11 Min19 2010 172 22  5 mo Known or
12 Chow20 2010 2076 16  8 mo Known or
13 Kristensen21 2011 312 16 mo patients w
CCTA ¼ coronary CT angiography; mo ¼ months; CAD ¼ coronary artery4. Prognostic utility of atherosclerotic plaque
features by CCTA
One potential advantage of CCTA is its ability to identify non-
obstructive CAD stenoses while assessing overall coronary ar-
tery plaque burden. Indeed, prior reports have observed that
approximately 60% of rupture-prone “vulnerable” plaques do
not exhibit an anatomically significant stenosis.24,25 In this re-
gard, several recent investigations have focused on additional
atherosclerotic plaque feature by CCTA, and whether these
findings can predict future acute coronary syndromes.
Motoyama et al interrogated culprit lesions in acute coronary
syndrome (ACS) by CCTA, and compared them with athero-
sclerotic plaques in patients presenting with stable angina
pectoris (SAP).26 The coronary plaques in ACS and SAP were
evaluated for the CT plaque characteristics, including vessel
remodeling, consistency of non-calcified plaque (NCP < 30 HU
or 30 HU < NCP < 150 HU), and spotty or large calcification.
CT profiling of culprit ACS and SAP lesions demonstrated
that positive remodeling (87% vs. 12%, p < 0.0001),
NCP < 30 HU (79% vs. 9%, p < 0.0001), and spotty calcification
(63% vs. 21%, p ¼ 0.0005) were significantly more frequent in
the ACS lesions. In a subsequent prospective study of 1059
patients who underwent CCTA, two atherosclerotic plaque
featuresdnamely positive arterial remodeling (PR) and low-
attenuation plaque (LAP)dindependently predicted incident
ACS during a follow-up of 27  10 months ACS (hazard ratio:
22.8, 95% confidence interval: 6.9 to 75.2, p < 0.001). There was
a significantly higher likelihood of ACS in patients with 2- or 1-
feature positive plaques compared to patients with 2- feature
negative plaques or no plaques (22.2% vs. 3.7% vs. 0.49%, log-
rank test p< 0.001) (Fig. 1 ). This study suggests the potential of
CCTA to expand its prognostic utility beyond stenosis severity
to include atherosclerotic plaque features not identifiable by
conventional stress testing and ICA.275. The CONFIRM registry
Although numerous studies have examined the potential for
prognostication using CCTA results,most have been limited to
small sample sizes in single-center studies. The Coronary CTscular event.
Population Slice of
CCTA
suspected CAD 16 and 64
suspected CAD 64
CAD 64
CAD with intermediate pre-test probability 64
CAD 64
CAD 64
CAD
l patients suspected for CAD with equivocal stress test 64
suspected CAD 64
suspected CAD 64
suspected CAD 64
ith NSTEMI 64
disease; NSTEMI ¼ non ST elevation myocardial infarction.
Fig. 1 e KaplaneMeier curve for development of ACS on the
basis of plaque characteristics patient stratification
according to the presence of 2- and 1-feature positive, and
2-feature negative plaques/no plaques. The y-axis
represents cumulative event-free rate (log-rank test,
p< 0.001). ACS [ acute coronary syndrome.
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tional Multicenter Registry, or CONFIRM, study was subse-
quently established as a large, prospective, multinational
dynamic observational cohort study of patients undergoing
64-slice CCTA.28 At present, the CONFIRM registry is
comprised of 2 phases. Phase I CONFIRM is a derivation cohort
that details demographic, clinical and CT findings for 27,125
consecutive patients (18 years of age), who were enrolled at
12 sites in 6 countries (United States, Canada, Germany,
Switzerland, Italy, South Korea) between 2005 and 2009. These
patients were followed for 2.3  1.1 years for a primary
endpoint of all-cause death. Phase II CONFIRM is a distinct
non-overlapping validation cohort, detailing identical ele-
ments to Phase I and with event follow-up for 4682 patients at
6 sites in 4 countries (United States, Canada, Austria, South
Korea). Patients enrolled in the CONFIRM study were followed
up after CCTA to identify adverse CAD events including all-
cause death, myocardial infarction, unstable angina, target
vessel revascularization, and CAD-related hospitalization.
This registry has provided numerous prognostic evidences by
CCTA.Fig. 2 e Overall obstructive CAD prevalence in patients
with non angina, atypical angina, and typical angina.
Observed prevalence (yellow bars) was lower than
expected prevalence (red bars) for angiographically
confirmed ‡50% stenotic coronary artery disease. (18% vs.
51%; p< 0.001). Ob-CAD [ obstructive coronary artery
disease, NonAng [ nonanginal chest pain,
AtypAng [ atypical chest pain, TypAng [ typical angina,
DFC [ Diamond and Forrester classification,
CASS [ coronary artery surgery study.6. Prognostic value of CCTA in patients
without known CAD (CONFIRM)
6.1. Symptomatic patients at intermediate pre-test risk
with calcium 0
Prior studies have demonstrated that a non-negligible pro-
portion of symptomatic patients presenting with chest pain
and CAC scores of 0 do, in fact, possess obstructive CAD; with
this findings especially noted among patients with a high pre-
test risk of obstructive CAD.29e32 However, the prevalence of
obstructive CAD among patients with CAC score of 0, who
have a lower pre-test risk of CAD, had not been previouslyexamined. Additionally, the prognostic importance of
obstructive CAD among patients with a CAC score of 0 and the
incremental prognostic value of CAC scoring over CCTA had
previously remained unclear. Villines and colleagues focused
on the prognostic value of CCTA in symptomatic patients with
CAC scores of 0.33 They identified 10,037 symptomatic patients
without known CAD, who underwent concomitant CCTA and
CAC scoring from CONFIRM registry, and assessed the prev-
alence of obstructive CAD with CAC score of 0 (Fig. 2).
Importantly, among patients with CAC score of 0, 84% had no
CAD, but 13% had non-obstructive CAD and 3.5% had
obstructive CAD, defined as 50% stenosis. In addition, they
noted that a CAC score > 0 had a high sensitivity and positive
predictive value for identifying obstructive CAD, 89% and 96%,
respectively at the cost of specificity and negative predictive
value, whichwere 59% and 29%, respectively. In amultivariate
analysis for prediction of obstructive CAD among symptom-
atic patients without CAC, family history of CAD and smoking
were found to be the strongest predictors.
Interestingly, the results of this study demonstrated that
there was no significant differences in all-cause mortality
irrespective of obstructive CAD among patients with CAC
score 0, a finding which may be related to sample size and
reduced statistical power (Fig. 3). However, among those with
CAC score of zero, patients with obstructive CAD experienced
higher rates (3.9%) of MACEdinclusive of all-mortality, non-
fatal MI, or coronary revascularizationdcompared to patients
(0.8%) with no CAD or non-obstructive CAD (p < 0.001). The
investigators explained these findings by pointing out that the
majority of patients with CAC scores of 0 and obstructive CAD
possessed single-vessel disease, with post-CCTA coronary
revascularization comprising the majority of “adverse” car-
diac events. Discriminatory power of a CAC > 0 by area under
the receiver operating characteristics curve (ROC), CAC scores
in symptomatic patients did not add incremental prognostic
information for predicting MACE when compared with CAD
Fig. 3 e Coronary artery stenosis on CCTA. Increasing
frequency of obstructive disease with increasing coronary
artery calcification (CAC) (Agatston) scores is
demonstrated. *p< 0.001 between groups.
CCTA [ coronary computed tomography angiography.
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CAC þ CCTA area under the curve ¼ 0.826; p ¼ 0.84) (Fig. 4).
6.2. CAD severity for prediction of all-cause death in
patients without known CAD: relation to age and gender
(CONFIRM)
Thehighdiagnostic performanceofCCTAforCADdetectionand
exclusion has been previously examined.3e5 Min et al examined
the all-cause mortality in relation to CAD severity in 24,775Fig. 4 e Survival according to CAC score and stenosis
severity. All-cause mortality-free survival among patients
according to CAC score and the severity of coronary artery
disease on coronary CTA.patients undergoing 64-detector row CCTA without known
CAD using the CONFIRM registry.34 In risk-adjusted analysis,
both per-patient obstructive (>50% stenosis) (HR: 2.60; 95% CI:
1.94e3.49; p < 0.0001) and non-obstructive (HR: 1.60; 95% CI:
1.18e2.16; p ¼ 0.002) CAD conferred increased risk of mortality
compared with patients without evidence of CAD. This data
highlights the clinical importance of non-obstructive
CADdwhich comprises a significant number of patients for
whom functional testingmight be expected to be negativedand
its strong relationship with all-causemortality.
The investigators also noted a doseeresponse relationship
to the number of coronary vessels exhibiting obstructive CAD
and all-causemortality, with increasing risk observed for non-
obstructive (HR: 1.62; 95% CI: 1.20 to 2.19; p ¼ 0.002), obstruc-
tive 1-vessel (HR: 2.00; 95% CI: 1.43 to 2.82; p< 0.0001), 2-vessel
(HR: 2.92; 95% CI: 2.00 to 4.25; p < 0.0001), or 3-vessel or left
main (HR: 3.70; 95% CI: 2.58 to 5.29; p < 0.0001) CAD (Fig. 5).
Importantly, the absence of CAD was associated with a very
low annualized death rate of 0.28%.
Furthermore, due to the size of this study, the investigators
were able to explore gender- and age-related differences in
CAD-related outcomes. Adjusted hazard ratios for the pre-
diction of all-cause mortality for non-obstructive CAD and 3-
vessel/left main disease for females were higher than for
males (HR: 4.21; 95% CI: 2.47e7.18; p < 0.0001 vs. HR: 3.27; 95%
CI: 1.96e5.45; p< 0.0001). Moreover, when stratified by age intoFig. 5 e Receiver operator characteristic curves: Major
adverse events. Receiver-operator characteristic curves of 4
models for predicting composite major adverse events in
8907 patients over a median of 2.1 years. CAC score
categories were defined as: 0, £100, 101e400, and>400.
Model 2 (Morise scoreD CAC category) compared to Model
1 (Morise score only): p< 0.001. Model 3 (Morise
scoreD number vessels ‡50% stenosis) compared to Model
2 (Morise score D CAC category): p< 0.001. Model 4
(Morise score D CAC category D number vessels ‡50%
stenosis) compared to Model 2 (Morise score D CAC
category): p< 0.001. Model 3 compared to Model 4:
p [ 0.84. AUC [ area under the curve; CAC [ coronary
artery calcification; CI [ confidence interval.
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 3 0 0e3 1 0 305<65 years vs. 65 years, younger subjects experienced higher
HR for death for 2-vessel (HR: 4.00; 95% CI: 2.16e7.40; p< 0.001,
HR: 2.46; 95% CI: 1.51e4.02; p ¼ 0.0003) or 3-vessel (HR: 6.19;
95% CI: 3.43e11.2; p < 0.0001, HR: 3.10; 95% CI: 1.954.92;
p < 0.0001) obstructive CAD when compared to older patients.
Furthermore, the investigators noted that although the pre-
test likelihood of obstructive CAD as estimated by the Dia-
mond Forrester tabular35,36 methods was highly predictive of
obstructive CAD by CCTA, it was not predictive for all-cause
mortality. These data suggest that a need for revision in the
way we assess stable symptomatic patients with suspected
CAD may be needed, and the CONFIRM investigators are
currently attempting to improve these methods. Currently,
the CONFIRM investigators are also investigating the prog-
nostic value of CCTA findings for MACE including but not
limited to all-cause death, such as non-fatal MI and late target
vessel revascularization, in patients without known CAD.37,387. Studies of prognostic value of CCTA
findings in selected population
7.1. Diabetes mellitus
Current American Diabetes Association guidelines endorse
cardiovascular disease primary prevention interventions for
patients with diabetes mellitus (DM) based on an observational
and population- based studies demonstrating excess cardio-
vascular riskanddeathattributable todiabetes.39However,prior
data examining the incremental risk of DM for future adverse
CAD events have generally lacked information regarding CAD
prevalence and severity based on CCTA findings.39e43 Rana et alFig. 6 e Unadjusted all-cause 3-year KaplaneMeier survival by th
dose response relationship of mortality to increasing numbers
CAD [ coronary artery disease, CCTA [ coronary computed toidentified 23,643 consecutive individuals undergoing 64-
detector row CCTA without known CAD from CONFIRM regis-
try (Diabetes Care 2012 in press). In this study, 3370 individuals
with DM who were propensity-matched in 1:2 fashion to 6740
unique non-DM individuals. The presence of CAD on CCTAwas
gradedasnone,non-obstructive (1e49%stenosis),orobstructive
(50%stenosis).DMindividualspossessedhigher frequenciesof
obstructive CAD (37% vs. 27%, p< 0.0001) and lower frequencies
of normal arteries (28%vs. 36%, p< 0.0001) compared tonon-DM
individuals. In addition, CAD extent was higher for DM vs. non-
DM individuals for obstructive 1-vessel disease [VD] (19% vs.
14%, p< 0.0001), 2-VD (9%vs. 7%, p< 0.0001) and3-VD (9%vs. 5%,
p<0.0001)withhigherper-segmentstenosis intheproximaland
mid segments of every coronary artery (p < 0.001 for all).
Furthermore, the risk of mortality for DM individuals was
significantly higher than those non-DM individuals for those
with no CAD, (HR: 3.64; 95% CI: 1.67e7.91; p ¼ 0.001), non-
obstructive CAD (HR: 5.25; 95% CI: 2.56e10.8; p < 0.001), 1-VD
(HR: 6.39; 95% CI: 2.98e13.7; p < 0.0001), 2-VD (HR 12.33: 95% CI:
5.62e27.1; p < 0.0001) and 3-VD (HR: 13.25; 95% CI: 6.15e28.6;
p < 0.0001) (Fig. 6). This data identified a heightened risk of
mortality that was more than 5-fold higher for DM individuals
with non-obstructive CAD, and almost 10-fold higher for those
with obstructive CAD compared to non-DM individuals. When
CADextentandseveritywasstratifiedonaper-vesselanalysisas
no CAD, non-obstructive CAD, obstructive1-VD, obstructive 2-
VD or obstructive 3-VD, the risk of mortality associated with
the presence of DM, resulted in a stepwise increase in risk, as
compared to those with non-DM individuals. The CONFIRM in-
vestigators are also currently evaluating the mortality risk for
DM and non-DM individuals enrolled into CONFIRM with a
longer follow-up period.e presence, extent and severity of CAD by CCTA. There is a
of vessels with obstructive coronary artery disease.
mography angiography.
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Studies examining CCTA have demonstrated increased mor-
tality related to CAD severity but have been limited to rela-
tively non-diverse ethnic populations. Hulten et al studied the
prognostic significance of CAD on CCTA according to ethnicity
for 16451 patients (60.1% Caucasian, 34.4% East Asian, and
5.5%Africa) without previous CAD followed for amedian of 2.0
years (interquartile range 1.4e3.2). The annualized incidence
of death or MI comparing obstructive (50% stenosis) to no
obstructive CAD among Caucasians was 2.2% vs. 0.7%
(adjusted hazard ratio [aHR] 2.77, 95% confidence interval [CI]
1.73 to 4.43, p < 0.001), 4.8% vs. 1.1% (aHR 6.25, 95% CI 1.12 to
34.97, p ¼ 0.037) among Africans, and 0.8% vs. 0.1% (aHR 4.84,
95% CI 2.24 to 10.9, p< 0.001) among East Asians. Compared to
other ethnicities, East Asians had a lower risk of events (aHR
0.25, 95% CI 0.16e0.38, p < 0.001).449. Prognostic value of CAD severity for
prediction of mortality risk: relation to left
ventricular ejection fraction
Previously, the examination of the prognostic value of CAD
severity and LVEF by CCTA has been limited to single center
studies.20 Chow et al examined the prognostic value of CAD
severity, LVEF, and clinical variables for predicting all-cause
mortality in 14,064 patients without known CAD who under-
went 64-slice CCTA.45 The National Cholesterol Education
Program-Adult Treatment Panel III risk was calculated as a
summary measure of clinical characteristics denoting risk. A
multivariate Cox model for predicting all-cause mortality
revealed that abnormal LVEF (HR: 2.74; 95% CI: 2.12e3.51)d
defined as <50% and CAD severity (HR: 1.58; 95% CI: 1.42e1.76)
were independent predictors after adjusting for clinical charac-
teristics. Furthermore, Chow also assessed the improvement of
reclassification based on CAD severity and LVEF using net
reclassification improvement (NRI) method.46 Patient reclassifi-
cation was significantly improved when LVEF was added to
clinical variables alone (NRI: 22.5%; p < 0.001) and when CAD
severity was added to the model of clinical variable and LVEF
(NRI:17.8%;p< 0.001).Atpresent, theCONFIRMinvestigatorsare
examiningwhether not only abnormal vs. normal LVEF isuseful
for enhancing risk stratification, but also whether the degree of
left ventricular dysfunction byCCTA improves risk stratification
for all-cause mortality.4710. Prognostic value of CCTA in patients with
known CAD (CONFIRM)
The utility of CCTA for risk stratification in coronary artery
bypass graft (CABG) patients has not been fully examined.
Small et al identified 657 CABG patients who had undergone
CCTA and assessed the prognostic value of unprotected cor-
onary territory (UCT) or a summary of native vessel disease
and graft patency: the coronary artery protection score
(CAPS).48 The investigators demonstrated that LVEF, creati-
nine, age, severity of native vessels disease were all univariateindependent predictors for all-cause mortality (p < 0.001). In
multivariate analysis, adjusted for the EuroSCORE, both UCT
(p¼ 0.004) and CAPS (p< 0.001) were found to be predictors for
all-cause mortality.11. Patients with acute chest pain syndrome
Particularly, the low negative likelihood ratio of CCTA sug-
gests its utility for efficient ACS. In addition to evaluating the
coronary artery anatomy of patients suspected of ACS in the
emergency department (ED), CCTA may also allow timely
diagnosis or exclusion of ACS and has the potential to be cost-
effective.49,50 Recently, several studies have also evaluated the
long-term outcome of patients discharged from the ED with
negative CCTA.51
Hollander et al prospectively evaluated 481 consecutive
low-to- intermediate risk patients who underwent CCTA in
the ED for evaluation of a potential ACS.52 At one year of
follow-up, there were 53 patients (11%) rehospitalized and 51
patients (11%) who received further diagnostic testing (stress
or catheterization). There was one death (0.2%; 95%
CI ¼ 0.01e1.15%) with unclear etiology, no MIs (0%; 95%
CI ¼ 0e0.76%), and no revascularization procedures (0%; 95%
CI ¼ 0e0.76%) during this time period. This study concluded
that for the low to intermediate risk chest pain population
presenting to the ED for evaluation with negative initial bio-
markers, ECG findings and TIMI risk score <2, CCTA is highly
predictive in excluding ACS.
ROMICAT trial was a similar prospective, double-blind
observational study that included 368 ED patients with acute
chest pain and a low to intermediate risk of ACS.53 From this
study, 368 patients who presented to the ED with acute chest
pain, negative initial troponin, and a non-ischemic electro-
cardiogram were followed for 2 years54 Investigators found
that the cumulative probability of 2-year MACE increased
across CCTA strata for CAD (no CAD 0%; non-obstructive CAD
4.6%; obstructive CAD 30.3%; log-rank p < 0.0001) and across
combined CCTA strata for CAD and regional wall motion ab-
normalities (RWMA) [no stenosis or RWMA 0.9%; 1-featur-
edeither RWMA [15.0%] or stenosis [10.1%], both stenosis and
RWMA 62.4%; log-rank p < 0.0001]. The C statistic for pre-
dicting MACE was 0.61 for clinical thrombolysis in myocardial
infarction risk score and improved to 0.84 by adding CT CAD
data and improved further to 0.91 by adding RWMA (both
p < 0.0001).12. Comparison of the prognostic utility of
CCTA to myocardial perfusion imaging (MPI)
CCTA has been compared as a prognostic tool with other
noninvasive testing, such as nuclear MPI. Shaw et al per-
formed a matched cohort comparison of patients with
suspected CAD referred for evaluation of new onset chest
pain with 693 and 3067 patients undergoing CTA and MPI.
They found that annual mortality rates were similar with
CCTA-detected Duke CAD index and nuclear MPI-identified
percentage of ischemic myocardium (p ¼ 0.53).55 Further-
more, van Werkhoven observed an incremental prognostic
Fig. 7 e Multivariable risk-adjusted hazards ratio for
coronary artery disease and severity on a per-vessel basis for
matched individuals with andwithout diabetes. Non-
DM[ non-diabetes mellitus; DM[ diabetes mellitus;
Nonobst[non-obstructiveCAD<50%maximalper-patient
stenosis; 1-VD[ 1-vessel obstructive CAD> 50% stenosis;
2-VD[ 2-vessel obstructive CAD> 50% stenosis;
3-VD[ 3-vessel obstructive CAD> 50% stenosis.
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 3 0 0e3 1 0 307value was seen when CCTA-detected CAD was combined
with MPI-identified ischemia looking at 541 patients who
had both multislice CT (MSCT) Fig. 8 and single photon
emission tomography (SPECT).56 Global chi-square tests
demonstrated that the addition of non-calcified plaque on
CCTA (2 segments with non-calcified plaque) resulted in
further incremental prognostic potential over baseline
clinical variables, MPI, and significant CAD (50% stenosis)
on MSCT (Fig. 7).13. CCTA for predicting complications of
percutaneous coronary inetervention (PCI)
complication
Nakazawa and his colleagues57 reported that lower CT plaque
density was significantly related to the “no-reflow” phenoFig. 8 e Incremental prognostic value of MSCT bar graph illustr
square value on the y axis) of MSCT. The addition of MSCT provi
variables and MPI. Furthermore, the addition of non-calcified p
results in further incremental prognostic information over base
stenosis) on MSCT. MSCT[multislice computed tomography co
CAD [ coronary artery disease.menon during percutaneous coronary intervention [PCI]
(67.010.1vs.97.837.2Hounsfieldunits,p¼0.018). Inaddition,
a signet ring-like appearancedthe so-called “napkin ring”
signdwas observed more frequently in patients with transient
no-reflow (55.6% vs 16.7%, p ¼ 0.013). Similarly, Kodama et al58
compared pre-PCI CCTA plaque characteristics for age-, sex-,
and culprit CAD-matched patients who underwent PCI during
the same period and did not develop slow flow. Calcium depo-
sition in the perimeter of a plaque, or circumferential plaque
calcification (CPC), was significantly more frequent in the slow
flow (SF) group (25 of 40, 63%) than theno-SF group (2 of 40, 5.0%)
(p < 0.001). The positive remodeling index was significantly
higher (1.5 [1.3e1.8]vs.1.2 [1.0e1.5];p<0.001)andplaquedensity
significantly lower (23.5 [9.5e40] HUvs. 45 [29e86] HU; p¼ 0.001)
in the SF group. The conditional logistic regression analysis
revealed that CPC, plaque density, and dyslipidemia were the
predictors of slowflow,withCPCbeing the strongest (odds ratio:
79; 95% CIl: 8e783, p < 0.0001). They concluded that CCTA-
verified CPC with low-attenuation plaque and positive remod-
eling were determinants of slow flow during PCI.
Uetani et al59 quantified coronary plaque in 189 consecu-
tive patients undergoing planned coronary intervention by
CCTA. The volume and fraction of low-attenuation plaque
(<50 Hounsfield units [HU]) in target lesions was found to be
independently associated with peri-procedural MI after
adjustment for multiple confounders. The fraction of moder-
ate attenuation (50e150 HU) or fibrous plaque inversely
correlated with post-procedural levels of cardiac biomarkers.
Similarly,Watanabe et al assessed coronary plaque feature
of culprit lesions in stable angina patients (n ¼ 107) with
normal pre-PCI cTnT levels underwent 64-slice MDCT before
PCI.60 Patients were divided into 2 groups according to pres-
ence (group I, n ¼ 36) or absence (group II, n ¼ 71) of post-PCI
cTnT elevation  3 times the upper limit of normal
(0.010 ng/ml) at 24 h after PCI. CCTA attenuation values were
significantly lower in group I than in group II (43.0
[26.5e75.7] HU vs. 94.0 [65.0e109.0] HU, p < 0.001). A positive
remodeling indexwas also significantly greater in group I thanating the incremental prognostic value (depicted by chi-
des incremental prognostic information to baseline clinical
laque on MSCT (‡2 segments with non-calcified plaque)
line clinical variables, MPI, and significant CAD (‡50%
ronary angiography; MPI[myocardial perfusion imaging;
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 3 0 0e3 1 0308in group II (1.20  0.18 vs. 1.04  0.15, p < 0.001). Spotty
calcification was also observed significantly more frequently
in group I than in group II (50% vs. 11%, p< 0.001). Multivariate
analysis demonstrated the presence of positive remodeling
(remodeling index > 1.05; odds ratio: 4.54; 95% confidence
interval: 1.36e15.9; p ¼ 0.014) and spotty calcification (odds
ratio: 4.27; 95% confidence interval: 1.30e14.8; p ¼ 0.016) to be
significant independent predictors for cTnT elevation. For
prediction of cTnT elevation, the presence of all 3 variables
(CCTA attenuation value <55 HU; remodeling index > 1.05,
and spotty calcification) showed a high positive predictive
value of 94%, with their absence notable conferring a high
negative predictive value of 90%. These investigators sug-
gested that, based upon these study findings, CCTA might be
useful for detecting which lesions are at high risk for
myocardial necrosis after PCI. Although these prior studies
demonstrated the potential of CCTA to predict PCI complica-
tion, future large sized prospective study must be performed
to generalize these findings.14. Conclusion
In addition to high diagnostic performance for anatomically
obstructive CAD, coronary CCTA findings of CAD convey
important prognostic information. Large international cohorts
such as theCONFIRMstudy have expanded the generalizability
of prior small studies. CCTAmeasures, including the presence,
extent and severity of CADdas determined by the number of
vessels with obstructive stenosis, segment involvement and
stenosis scores, and stenosis locationdhave been well vali-
dated by the CONFIRM registry. Future studies are still needed
in this relatively nascent field, with newer CT tech-
nologiesdincluding rest-stress myocardial perfusion and
noninvasive calculation of fractional flow reservedmay
further expand the diagnostic and prognostic abilities of CCTA.Conflicts of interest
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